Kestra Medical Technologies (KMTS) Research & Development (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported Research & Development for 3 consecutive years, with $5.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 4.6% year-over-year to $5.6 million in Q2 2026; TTM through Apr 2026 was $19.5 million, a 24.49% increase from a year earlier, with the FY2026 full-year figure at $19.5 million, up 24.48% from the prior year.
• Research & Development was $5.6 million for Q2 2026 at Kestra Medical Technologies, up from $5.0 million in the prior quarter.
• Over five years, Research & Development peaked at $5.6 million in Q2 2026 and troughed at $3.4 million in Q1 2025.
• A 3-year average of $4.3 million and a median of $3.9 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development retreated 10.23% in 2025 and surged 48.29% in 2026, its largest moves.
• Over 3 years, Research & Development stood at $3.5 million in 2024, then soared by 39.01% to $4.9 million in 2025, then advanced by 15.5% to $5.6 million in 2026.
• The last three Research & Development figures came in at $5.6 million (Q2 2026), $5.0 million (Q1 2026), and $4.9 million (Q4 2025), per Business Quant data.